The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with HER2-positive early breast cancer who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results